BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2015
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BIOFLOW-III
- Sponsors BIOTRONIK
- 30 May 2013 Primary outcomes reported at EuroPCR, according to a Biotronik media release. Outcomes also reported in the media release.
- 30 May 2013 Status changed from active, no longer recruiting to completed, baseed on information in a Biotronik media release.
- 30 May 2013 Primary endpoint 'Target-lesion-failure-rate at 12 months' has been met, as reported in a Biotronik media release.